Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Filings indexed 1,019 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
8-K - EyePoint, Inc. (0001314102) (Filer)
Regulatory Filings
2026-05-06 English
8-K - EyePoint, Inc. (0001314102) (Filer)
Regulatory Filings
2026-04-13 English
4 - EyePoint, Inc. (0001314102) (Issuer)
Director's Dealing
2026-03-24 English
8-K - EyePoint, Inc. (0001314102) (Filer)
Regulatory Filings
2026-03-20 English
8-K - EYEPOINT PHARMACEUTICALS, INC. (0001314102) (Filer)
Regulatory Filings
2026-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.